Compare ALLT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | AKBA |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 343.4M |
| IPO Year | 2006 | 2014 |
| Metric | ALLT | AKBA |
|---|---|---|
| Price | $7.47 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $12.40 | $4.67 |
| AVG Volume (30 Days) | 251.8K | ★ 8.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.12 | $0.81 |
| 52 Week High | $11.92 | $3.19 |
| Indicator | ALLT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 49.90 |
| Support Level | $7.37 | $0.82 |
| Resistance Level | $7.62 | $1.52 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 19.51 | 91.63 |
Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.